BioNTech’s Bold Leap: From Covid-19 Vaccines to Cutting-Edge Cancer Therapies
BioNTech is transitioning from its Covid-19 vaccine success to pioneering mRNA-based cancer therapies. The company experienced a decrease in quarterly earnings and annual revenue in 2024, yet exceeded market expectations.…